Naminidil
| Clinical data | |
|---|---|
| Other names | BMS-234303; BMS234303 |
| Routes of administration | Topical [1] |
| Drug class | ATP-sensitive potassium channel opener; Vasodilator |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C15H19N5 |
| Molar mass | 269.352g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Naminidil (INN Tooltip International Nonproprietary Name, USAN Tooltip United States Adopted Name; developmental code name BMS-234303) is an ATP-sensitive potassium channel opener with vasodilator activity which was under development as a topical medication for the treatment of androgenic alopecia (pattern hair loss) but was never marketed.[2] [3] [1] The drug was under development by Bristol-Myers Squibb and reached phase 2 clinical trials by 2001.[2] One of the phase 2 trials compared naminidil, minoxidil, and placebo for alopecia.[1] However, no results of the study appear to have been made available.[1] Development of naminidil was discontinued by 2008.[2] In terms of chemical structure, naminidil is a guanidine derivative and is structurally distinct from minoxidil.[2] [4]
See also
[edit ]References
[edit ]- 1 2 3 4 Poulos GA, Mirmirani P (February 2005). "Investigational medications in the treatment of alopecia". Expert Opinion on Investigational Drugs. 14 (2): 177–184. doi:10.1517/13543784.14.2.177. PMID 15757393.
- 1 2 3 4 "Naminidil". AdisInsight. 17 January 2008. Retrieved 23 July 2025.
- ↑ "Delving into the Latest Updates on Naminidil with Synapse". Synapse. 20 July 2025. Retrieved 23 July 2025.
- ↑ "Naminidil". PubChem. U.S. National Library of Medicine. Retrieved 24 July 2025.
This dermatologic drug article is a stub. You can help Wikipedia by adding missing information.